Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

WCLC 2022 | The macrophage migration inhibitory factor (MIF) as a therapeutic and diagnostic target

Christine Landlinger-Schubert • 7 Aug 2022
WCLC 2022
Lung Cancer Antibodies ON203

Christine Landlinger-Schubert, PhD, OncoOne, Klosterneuburg, Austria, talks on the macrophage migration inhibitory factor (MIF) as a target for the treatment of both solid tumors and chronic inflammatory diseases, as well as a diagnostic tool. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.

More from Christine Landlinger-Schubert

0:57
ON203: the anti-oxMIF antibody targeting solid tumors
Christine Landlinger-Schubert • 7 Aug 2022
1:45
The rationale behind the MIF-targeting antibody ON203 for solid tumors
Christine Landlinger-Schubert • 7 Aug 2022

Related Videos

0:45
Assessing treatment options for lung cancer with interstitial lung disease
Matthew Hatton • 18 Apr 2024
2:26
Targeting KRAS mutations in lung cancer
Thomas Newsom-Davis • 18 Apr 2024
7:37
What is the optimal follow-up for lung cancer long term survivors?
Robert Rintoul • 19 Apr 2024
1:47
Assessing follow-up strategies in post-surgical lung cancer: insights from a Phase III trial
Robert Rintoul • 19 Apr 2024
The content of VJOncology is intended for healthcare professionals